|
| |
Agilent Technologies and BioNanomatrix to Develop
Genetic Analysis System Using Nanoscale Whole Genome Imaging Technology
SANTA CLARA, Calif., and PHILADELPHIA, Nov. 7, 2007
-- Agilent Technologies Inc. (NYSE: A) and BioNanomatrix Inc. today
announced that they have entered into a collaboration to develop a new genetic
analysis system combining the two companies’ technologies. BioNanomatrix, which
develops breakthrough nanoscale whole genome imaging and analytic platforms,
will apply its innovative nanoscale single molecule imaging technology to
develop consumable chips and reagents, while Agilent will develop the
measurement instrumentation platform for the system.
“This collaboration with Agilent provides us with the opportunity to join forces
with a global life sciences leader to accelerate the development of our unique
nanoscale whole genome imaging technology,” said Dr. Michael Boyce-Jacino, chief
executive officer of BioNanomatrix. “We now have a partner with strong life
sciences expertise and capabilities committed to working with us to develop key
life-sciences applications, such as assays for genotoxicity and cytogenetics, as
well as potentially DNA sequencing.”
BioNanomatrix is developing pioneering technology that enables nanoscale single
molecule identification and analysis of the entire genome, delivering
single-molecule sensitivity in a highly parallel format. The company’s patented
analytic platform based on this technology has the potential to provide rapid,
comprehensive and cost-effective ultra-high resolution analyses of DNA. The two
companies intend to collaborate closely in the development of an integrated
system and applications.
“BioNanomatrix’s unique nanoscale whole genome imaging and analysis technology,
with sensitivity at the level of the single molecule, has the potential to
enable a number of important new applications for life sciences research and
clinical medicine,” said Nick Roelofs, vice president and general manager of the
Life Sciences Solutions Unit at Agilent. “We are committed to continuing our
leadership in developing important new technologies and solutions for our
customers, and we look forward to collaborating with the BioNanomatrix team to
enable these powerful new capabilities to reach the marketplace.”
Further details of the agreement were not disclosed.
About BioNanomatrix
BioNanomatrix is developing breakthrough nanoscale whole genome imaging and
analytic platforms for applications in clinical genetics, cancer diagnostics and
other biomedical applications. The company is applying its expertise in
nanochips, nanodevices and nanosystems to develop its patented platform
technology to provide fast, comprehensive, and low-cost analysis of genomic,
epigenomic and proteomic information with sensitivity at the single cell/single
molecule level. BioNanomatrix’s technologies are licensed exclusively from
Princeton University. Founded as a spin-out of Princeton University in 2003, the
company is headquartered in Philadelphia, Penn. For more information, visit
www.BioNanomatrix.com .
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement
company and a technology leader in communications, electronics, life sciences
and chemical analysis. The company’s 19,000 employees serve customers in more
than 110 countries. Agilent had net revenue of $5.0 billion in fiscal year 2006.
Information about Agilent is available on the Web at
www.agilent.com .
# # #
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is
available on the Agilent news site at
www.agilent.com/go/news .
Press release URL:
http://www.agilent.com/about/newsroom/presrel/2007/05nov-al07002.html
Additional metadata keywords (for Web use only): genome, nanoscale, imaging, DNA
EDITORIAL CONTACTS:
Claudia Hachtel, Agilent Technologies
+49-7243-602 100
claudia_hachtel@agilent.com
Nicki Muir, Alto Marketing
+44-1489-55 76 72
nickim@alto-marketing.com
Sarah Perceval, Alto Marketing
+44-1489-55 76 72
sarahp@alto-marketing.com | |
|
